CompletedNot Applicable

Eosinophilic Esophagitis Steroid Safety Study

Greece, Israel, Italy55 participantsStarted 2019-10-07

Plain-language summary

This observational study will follow pediatric patients with eosinophilic esophagitis who are scheduled to begin topical steroid treatment, from the initiation of treatment longitudinally to determine the safety profile of the drug.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \<18 years at the time of enrollment.
✓. Males and Females are included.
✓. Patients diagnosed with EoE as defined by age appropriate signs of esophageal dysfunction (in older children and adolescents - dysphagia, impacted food bolus, foreign body impaction, vomiting, and GERD not responsive to high dose proton pump inhibitors. In infants and young children - failure to thrive, poor feeding, vomiting, food bolus impaction)
✓. Histopathological finding of ≥15 eosinophils/high power field (X400) on at least one esophageal biopsy.
✓. After discussing the available treatment options with the gastroenterologist, the patient has chosen oral topical steroid treatment (either as a first treatment or after failure of other dietary or medical treatment).

Exclusion criteria

✕. Known alternative causes of esophageal eosinophilia.
✕. Legal guardian unable or unwilling to sign informed consent..
✕. Known allergy to topical steroids ingredients
✕. Patient will not be available for follow-up for at least the 3 month assessment and ACTH test.
✕. Known pregnancy
✕. Use of oral systemic steroids in the 6 months prior to inclusion in the study. Use of systemic steroids once in the study will not lead to study termination, but such use will need to be reported in the medication changes and use page of the following visit.

What they're measuring

Adrenal suppression

Timeframe: 3 months

Adrenal suppression

Timeframe: 12 months

Growth failure

Timeframe: 12 months

Growth failure

Timeframe: 36 months

Trial details

NCT IDNCT04416217

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Eosinophilic Esophagitis trials